Composition: Each gram of gel contains Recombinant Human Epidermal Growth Factor 10 µg/gm, 1.0% w/w silver sulfadiazine, 0.20% w/w chlorhexidine gluconate. Indications: SLVRGEN^® is primarily used for treatment of 1st & 2nd degree burns and also can be used for abrasions, incisions, minor cuts and wounds. Contraindications: Sulfonamide therapy is known to increase the possibility of kernicterus; SLVRGEN^® should not be used in pregnant females at term, in premature infants, or in newborn infants in the first month of life. rh-EGF is generally well tolerated. However, the product should not be used on patients with a known sensitivity to any of its components. Dosage and administration: The burn wounds should be cleaned and SLVRGEN^® cream applied over all the affected areas. SLVRGEN^® should be re-applied at least every 24 hours. Precautions: SLVRGEN^® should be used with caution if hepatic or renal function is significantly impaired. Leukopenia has been reported following the use of SSD-Ag, especially on patients with large area burns. This may be a drug-related effect, and often occurs 2 to 3 days after treatment has commenced. It is usually self-limiting and therapy with SSD-Ag does not normally need to be discontinued, as the WBC count usually returns to the normal range in a few days. SLVRGEN^® should only be used in badly burned pregnant women if the benefit to the patient outweighs the risk to the fetus. SSD-Ag should not be used when the patient is near term. Storage and stability: Store at room temperature (25°C.) Keep the cap tightly closed after use. After completion of treatment, any cream remaining in the tube should be discarded. Adverse events: Adverse events may occur such as pain, itching, rash, skin irritation, fever, abdominal pain and headache. Clinical data: A Phase 4, Post-marketing surveillance study was performed, on a total of 450 Patients with superficial and partial thickness burn were recruited at 11 clinical centres across India. The combination of silver sulfadiazine, chlorhexidine and recombinant epidermal growth factor in SLVRGEN^® offers the advantage of the broad spectrum of activity, synergistic antimicrobial action, a very low potential for the development of resistant strains and early healing of wound due to an increased rate of Cell Proliferation, Maturation and Epithelization. Pharmacodynamic properties: Silver sulfadiazine acts on the cell membrane and cell wall of microorganisms to produce its bactericidal effect. Chlorhexidine gluconate is adsorbed onto the cell walls of microorganisms, which causes leakage of intracellular components. At low concentrations, chlorhexidine gluconate is bacteriostatic; at higher concentrations, it is bactericidal. Epidermal Growth Factor (EGF) peptide induces cellular proliferation through the EGF receptor, which has a tyrosine kinase cytoplasmic domain, a single transmembrane domain and an extracellular domain involved in EGF binding and receptor dimerization. Pharmacokinetic properties: The degree of silver sulfadiazine uptake will significantly depend upon the surface area of the wound and the dosing regimen. No silver deposits have been observed in renal tissues, usually, sulfadiazine is excreted in the urine.¹ Chlorhexidine is poorly absorbed through the intact skin; systemic absorption may occur from the broken skin. Chlorhexidine is metabolized in the liver; it is excreted largely unchanged in faces through the bile.² 1. https://www.pdr.net/drug-summary/Silvadene-silver-sulfadiazine-2781. 2. Product monograph prchlorhexidine alcohol free. Chlorhexidine Gluconate Oral Rinse, 0.12% w/v House Standard. Euro-Pharm International Canada Inc. 9400 Boul. Langelier Montreal, Quebec H1P 3H8.